Physician profile
Aline Studstill
NPI 1972137040
$4,482.53
in general payments reported to CMS, 2019-2025
22 companies · $934 in 2025
The $934 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70.96 · 2022: $440 · 2023: $1,437 · 2024: $1,601 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,827 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,826.95 |
| Education | $145.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $712.07 | 2023-2025 | Caplyta |
| Harmony Biosciences LLC | $669.42 | 2023-2025 | Wakix |
| Abbvie INC. | $529.07 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $382.29 | 2022-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $303.60 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $248.37 | 2022-2024 | Azstarys |
| Tris Pharma INC | $241.94 | 2022-2024 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $212.55 | 2023-2024 | Spravato |
| Lundbeck LLC | $176.60 | 2022-2025 | Rexulti |
| Neos Therapeutics, LP | $169.59 | 2022-2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $149.81 | 2023-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $139.94 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $98.17 | 2025 | Fanapt |
| Almatica Pharma LLC | $83.71 | 2023-2025 | Loreev Xr, Gralise, Teriparatide |
| E.R. Squibb & Sons, L.L.C. | $74.34 | 2024-2025 | Cobenfy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $61.08 | 2022-2025 | Aristada, Lybalvi |
| Pfizer INC. | $55.11 | 2021 | |
| Neurocrine Biosciences, INC. | $48.54 | 2022-2023 | Ingrezza |
| Collegium Pharmaceutical, INC. | $48.05 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $45.04 | 2022-2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $17.39 | 2025 | Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $15.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aline Studstill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.